Marc Le Borgne
University Lyon 1
Marc Le Borgne has completed his PhD at the age of 31 years from Nantes Atlantic University after Pharmacy studies (6 years). He is the director of EA 4446 B2MC, a research group dedicated to Drug Design, Synthesis and Structural Optimization. He has published more than 60 papers in reputed journals and is serving as an editorial board member of Pharmaceuticals (since 2016). He gave some invited lectures abroad (Saarbrück, Duesseldorf, Oslo, Tromsø, Bergen, Debrecen, Sacramento, Helsinki, Oulu...). He is developing bioactive small molecules targeting kinases, efflux pumps and CYPs
Design, synthesis and structural optimization of functionalized small molecules as anticancer agents (CK2, Dyrks), efflux pump inhibitors (Pg-p, BCRP) and anti-infective agents (CYP51, vaccines). Some scaffolds developed: indole, naphthyridine, indeno[1,2-b]indole, steroids, peptidomimetics, polysialic acid.